ASGCT2024: FDA’s Marks on Accelerated Approval, Gene Therapy Costs and More 5/8/2024

Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy 5/8/2024

AstraZeneca Withdraws COVID-19 Vaccine Worldwide as Demand Craters 5/8/2024

Pfizer Halts Dosing in Late-Stage DMD Study Following Death of Young Patient 5/8/2024

Lykos Therapeutics’ MDMA Therapy for PTSD to Face FDA Adcomm 5/8/2024

ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird 5/8/2024

Generative AI Finds Its Footing in Drug Development 5/8/2024

BMS, J&J Losses Not the End of IRA Legal Battle 5/8/2024

Biopharma Layoff Tracker 2024: Marinus, Kenvue, Emergent and More Cut Staff 5/8/2024

Merck Snaps Up Small Startup in $208M Deal, Seeks to Improve Safety of ADCs 4/8/2024

BMS Sees Early ROI for $14B Karuna Buy with Phase III Schizophrenia Win 4/8/2024

ACC24 Roundup: Novo, Ionis Tout Cardio Victories and Boehringer, Lilly Disappoint 4/8/2024

5 Successful Phase III Oncology Trials in Q1 4/8/2024

The Next Wave of ADCs Could Treat Evasive Solid Tumors 4/8/2024

AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for Enhertu 4/8/2024

FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease 4/8/2024

Opinion: The Next Generation of ADCs Will Improve Cancer Treatment 4/8/2024

Flagship-Backed Prologue Launches with $50M to DELVE into Viral Proteome 5/7/2024

Vertex Touts 13% Revenue Jump, Beats Profit Estimates on Strong Cystic Fibrosis Performance 5/7/2024

AAV Manufacturing Takes Center Stage at ASGCT24 5/7/2024